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           Mast cells play a central role in IgE-dependent 
allergic diseases. Recently, mast cells have also 
been recognized as prominent immune eff  ector 
cells. Mast cells constitutively express the high 
affi   nity IgE receptor (Fc    RI) on their surface 
(  1  ). Aggregation of Fc    RI initiates a cascade of 
activating signaling events leading to the pro-
duction of mast cell mediators. Activation sig-
nals are needed for the production and secretion 
of proinfl  ammatory mediators. Activation sig-
nals are subsequently inhibited by negative sig-
nals that are required for mast cells to return to 
their basal resting condition (  2  ). Thus, Fc    RI-
mediated activation and subsequent inhibition 
are highly ordered, sequential molecular events. 
The nature of this negative signaling event after 
Fc    RI-mediated mast cell activation is the sub-
ject of this study. 
  Fc    RI consists of an IgE-binding      subunit, 
a signal-amplifying      subunit, and two signal-
initiating      subunits (  3  ). Fc    RI-mediated activa-
tion events have been extensively studied. The 
widely accepted model is as follows: upon cross-
linking of the Fc    RI, the Src family protein tyro-
sine kinases Lyn and Fyn are activated (  3  –  5  ). Lyn 
phosphorylates tyrosine residues of the immuno-
receptor tyrosine-based activation motif in the 
     and      subunits (  3, 4  ). Syk is then recruited to 
the      subunit and activates a multitude of pro-
tein kinases. Fyn functions to phosphorylate 
Gab2, which is involved in Fc    RI-induced acti-
vation of phosphatidylinositol 3 kinase (PI3K) 
(  5  ). Concerted actions of Lyn and Fyn activate 
several signaling pathways, including I    B  –  NF-
    B, NFAT, mitogen-activated protein kinases 
(MAPKs), and PI3K  –  Akt, leading to mast cell 
degranulation and production of infl  ammatory 
cytokines and lipid mediators (  1, 3  ). Most of 
these signal events are enzymatic reactions and 
occur within seconds to minutes. 
  In addition to the immediate enzymatic ac-
tivation of protein kinases, we recently demon-
strated that   Egr1  -defi   cient mast cells showed 
impaired Fc    RI-induced TNF and IL-13 
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  Aggregation of the high affi  nity IgE receptor (Fc    RI) activates a cascade of signaling 
events leading to mast cell activation. Subsequently, inhibitory signals are engaged for 
turning off activating signals. We identifi  ed that regulator of calcineurin (Rcan) 1 serves as 
a negative regulator for turning off Fc    RI-mediated mast cell activation. Fc    RI-induced 
Rcan1 expression was identifi  ed by suppression subtractive hybridization and verifi  ed by 
real-time quantitative polymerase chain reaction and Western blotting. Defi  ciency of 
  Rcan1   led to increased calcineurin activity, increased nuclear factor of activated T cells and 
nuclear factor     B activation, increased cytokine production, and enhanced immunoglobulin 
E  –  mediated late-phase cutaneous reactions. Forced expression of Rcan1 in wild-type or 
  Rcan1  -defi  cient mast cells reduced Fc    RI-mediated cytokine production.   Rcan1   defi  ciency 
also led to increased Fc    RI-mediated mast cell degranulation and enhanced passive cutane-
ous anaphylaxis. Analysis of the   Rcan1   promoter identifi  ed a functional Egr1 binding site. 
Biochemical and genetic evidence suggested that Egr1 controls Rcan1 expression. Our 
results identifi  ed Rcan1 as a novel inhibitory signal in Fc    RI-induced mast cell activation 
and established a new link of Egr1 and Rcan1 in Fc    RI signaling. 
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trol cDNA (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20081140/DC1). The PCR products of the 
subtraction were cloned and sequenced after a diff  erential hy-
bridization procedure to exclude false positives. Surprisingly, 
among 33 positive clones sequenced, 8 clones matched the 
  Rcan1   gene (exons 4, 5, 6, and 7), suggesting the abundance of 
this gene product in Fc    RI-activated mast cells (Table S1 and 
Fig. S2). One clone matched the   Egr1   gene (Table S1). Re-
verse Northern blot analysis using one of the identifi  ed Rcan1 
clones (2C3) as a probe confi  rmed the increased expression of 
Rcan1 in the TNP-BSA  –  stimulated sample (  Fig. 1 A  ).   
  We further examined the kinetics of Rcan1 expression in 
mast cells in response to Fc    RI aggregation using real-time 
quantitative PCR. Given that the expression of any   Rcan   
family members by mast cells has not been reported previ-
ously, we also examined Rcan2 and Rcan3. Two Rcan1 iso-
forms have been reported, the isoform Rcan1-4 encoded by 
exons 4, 5, 6, and 7, and the isoform Rcan1-1 encoded by 
exons 1, 5, 6, and 7 (  17  ). Total RNA was isolated from 
TNP-BSA  –  treated mouse BMMCs and analyzed by real-
time quantitative PCR for two Rcan1 isoforms, as well as for 
Rcan2 and Rcan3. Levels of Rcan mRNA expression were 
normalized to GAPDH in each sample. Rcan1-1 and Rcan3 
showed low levels of expression under resting conditions, 
whereas Rcan2 was undetectable in both resting and acti-
vated cells (unpublished data). Among these Rcan family 
members tested, Rcan1-4 was the only member found to be 
up-regulated by TNP-BSA stimulation. The Rcan1-4 level 
in the unsti  mulated mast cells was undetectable. Rcan1-4 
expression peaked at 60 min after TNP-BSA stimulation 
(  Fig. 1 B  ). PCR-amplifi  ed   Rcan1   products (Rcan1-4) were 
also separated in agarose gels and visualized by ethidium bro-
mide staining. A representative gel is presented in   Fig. 1 C  . 
Strong Rcan1-4 expression can be seen at 60 min after TNP-
BSA stimulation. 
  To determine Rcan1 expression at the protein level, IgE-
sensitized mast cells were treated with TNP-BSA for various 
times and subjected to Western blot analysis. Rcan1 expres-
sion was observed in TNP-stimulated mast cells (  Fig. 1 D  ). 
  Development of mast cells in the absence of Rcan1 
  To examine a role of Rcan1 in IgE-dependent mast cell 
ac  tivation, we chose to obtain mouse BMMCs from   Rcan1  -
defi  cient mice. Exons 5 and 6 are deleted from the   Rcan1   gene. 
Thus, these mice are defi  cient in   Rcan1   products (Rcan1-1 and 
Rcan1-4) (  18  ). Bone marrow cells from   Rcan1  -defi  cient and 
wild-type mice were cultured in conditioned medium and were 
analyzed by fl  ow cytometry for c-kit and IgE receptor ex-
pression. No diff  erence of the c-kit and IgE receptor expres-
sion after 5 wk of culture was observed between wild-type and 
  Rcan1  -defi   cient cells (Fig. S3 A, available at http://www
.jem.org/cgi/content/full/jem.20081140/DC1). BMMCs were 
also used for Toluidine blue staining. Morphologically, no 
diff  erence was observed between   Rcan1  -defi  cient and wild-
type mast cells (Fig. S3 B). This result suggests that mast cells 
mature normally in the absence of Rcan1. 
production (  6  ). The de novo synthesis of the transcription 
factor Egr1 is required for the full responsiveness of mast cells 
in the production of cytokines in response to IgE stimulation 
(  6  ). The promoter region of infl  ammatory cytokines such as 
TNF contains multiple transcription factor binding sites, in-
cluding those for NF-    B, NFAT, and Egr1 (  7, 8  ). Accord-
ingly, the coordinated action of immediate enzymatic 
activation together with newly synthesized transcription fac-
tor Egr1 contributes to the magnitude of mast cell activation. 
As Fc    RI aggregation  –  induced Egr1 expression occurs from 
15 min to 1 h after antigen stimulation, it appears that Egr1 
contributes to the later phase of Fc    RI-mediated signals (  6  ). 
Intriguingly, an opposing biological eff  ect of Egr1, both the 
stimulatory and inhibitory eff  ects on gene expression, has 
been reported (  9  –  11  ). Such dual eff  ects suggest that Egr1 may 
initiate both activation and inhibition signals. 
  Transcription factors NFAT and NF-    B regulate the tran-
scription of multiple cytokines in mast cells. These transcription 
factors are sequestered in the cytoplasm under resting condi-
tions and translocate to the nucleus upon Fc    RI activation 
(  12, 13  ). Calcineurin is capable of regulating NFAT and NF-    B 
nuclear translocation (  14, 15  ). Blocking the calcineurin  –  NFAT 
pathway by using pharmaceutical molecules has been shown to 
be an eff  ective means for treating allergic infl  ammation, high-
lighting the importance of this pathway in allergy (  16  ). 
  A new family of regulators of calcineurin (Rcans), includ-
ing Rcan1, Rcan2, and Rcan3, has been shown to modulate 
calcineurin activity under physiological and pathological 
conditions (  17  ). In this study, we identifi  ed Rcan1 as an en-
dogenous negative regulator in Fc    RI-mediated signaling. 
  Rcan1   defi  ciency had few eff  ects on the early phase (5  –  20 min) 
of Fc    RI-induced NFAT and I    B activation but strongly 
enhanced the late-phase Fc    RI-mediated NFAT activation 
(3  –  6 h) and I    B phosphorylation (1 h), leading to increased 
cytokine production in vitro and enhanced late-phase cuta-
neous allergic reaction in vivo.   Rcan1   defi  ciency also showed 
increased Fc    RI-mediated mast cell degranulation in vitro 
and increased passive cutaneous anaphylaxis in vivo. Accord-
ingly, Rcan1 is a novel negative regulator in Fc    RI-induced 
mast cell activation. In addition, biochemical and genetic 
analyses revealed a new link between Egr1 and Rcan1 in 
Fc    RI-mediated signaling. 
    RESULTS   
  Fc    RI aggregation induces Rcan1 expression 
  Suppression subtractive hybridization (SSH) allows us to iden-
tify target genes even without a prerequisite knowledge of 
these genes. SSH was used to identify genes that are diff  eren-
tially expressed in Fc    RI-activated mast cells. Total RNA 
from TNP-BSA  –  treated or untreated mouse bone marrow  –
  derived mast cells (BMMCs) were used to generate double-
stranded cDNAs. A subtracted cDNA library was constructed 
to enrich the transcripts that were diff  erentially expressed by 
mast cells after TNP-BSA stimulation. The subtraction effi   -
ciency was evaluated by comparing GAPDH cDNA levels by 
PCR in serial dilutions of subtracted and nonsubtracted con-JEM VOL. 206, January 19, 2009 
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  Increased activation of NFAT and NF-    B pathways 
but not MAPKs in   Rcan1  -defi  cient BMMCs 
  To determine the specifi   c signaling pathways regulated by 
Rcan1 in Fc    RI-mediated mast cell activation, we examined 
activation of NFAT, NF-    B, and MAPK pathways in   Rcan1  -
defi  cient BMMCs. For the study of NFAT pathway activation, 
an NFAT luciferase assay, EMSA, and an immunofl  uorescence 
assay were used.   Rcan1  -defi  cient and wild-type BMMCs were 
transfected with NFAT luciferase plasmid. Cells were then sen-
sitized with anti-TNP IgE and activated with TNP-BSA for 
18 h. A signifi  cant increase in NFAT luciferase activity was 
seen in   Rcan1  -defi  cient BMMCs after TNP-BSA stimulation 
compared with that in wild-type BMMCs (  Fig. 2 A  ).   These data 
suggests that Rcan1 is a negative regulator of IgE-dependent 
NFAT activation. 
  To further examine NFAT activation, an NFAT DNA 
probe was synthesized based on the NFAT binding sequence 
in the mouse   IL-13   promoter and labeled with   32  P. Nuclear 
extracts from   Rcan1  -defi   cient and wild-type BMMCs after 
TNP stimulation for various times (5  –  360 min) were subjected 
to EMSA using a   32  P-labeled NFAT probe. As shown in 
  Fig. 2 B  , NFAT activities were enhanced in   Rcan1  -defi  cient 
BMMCs at the later time points (180 and 360 min) after TNP 
stimulation. In contrast, little diff  erence was observed at the 
early time points (5  –  60 min) between   Rcan1  -defi  cient and 
wild-type BMMCs. This result suggests that Rcan1 is a nega-
tive regulator by turning off   the TNP-activated NFAT signal. 
Densitometry analysis of NFAT DNA binding activity is 
shown in   Fig. 2 C  . The binding specifi  city of nuclear proteins 
to the NFAT DNA sequence was verifi  ed through competi-
tive binding by the nonradioisotope-labeled NFAT probe but 
not by a mutant probe (  Fig. 2 D  ). The binding specifi  city was 
further verifi  ed by supershift assay. Nuclear protein binding to 
the NFAT probe was strongly blocked by anti-NFATc1 anti-
body or by anti-NFATc2 antibody (  Fig. 2 E  ). 
  To examine whether Rcan1 regulates calcineurin activity 
in mast cells,   Rcan1  -defi  cient and wild-type BMMCs were 
sensitized with IgE and treated with TNP-BSA. BMMCs were 
then lysed and subjected to analysis for calcineurin activity. In-
creased calcineurin activity was observed in   Rcan1  -defi  cient 
BMMCs (  Fig. 2 F  ). 
  To examine NFAT nuclear translocation, IgE-sensitized 
BMMCs were treated with TNP-BSA for 6 h. Cells were 
then fi  xed, permeabilized, and stained with anti-NFATc1 
antibody. The cell nucleus was visualized by DAPI staining. 
TNP-induced NFAT nuclear translocation was visible in wild-
type and   Rcan1  -defi   cient cells. Enhanced NFAT nuclear 
translocation was seen in   Rcan1  -defi  cient cells when com-
pared with wild-type cells (Fig. S4, available at http://www
.jem.org/cgi/content/full/jem.20081140/DC1). 
  In light of a critical role for transcription factor NF-    B in 
the regulation of gene expression (  19  ), we examined whether 
Rcan1 is required in Fc    RI-mediated NF-    B pathway activa-
tion.   Rcan1  -defi  cient BMMCs and wild-type cells were trans-
fected with NF-    B luciferase plasmid. After sensitization with 
anti-TNP IgE, BMMCs were stimulated with TNP-BSA for 5 h. 
    Figure 1.         IgE-dependent Rcan1 expression by mast cells.   (A)  RNAs 
from TNP-BSA  –  treated (TNP) and untreated (NT) mouse BMMCs were 
reversed transcribed into cDNA and blotted with a GAPGH probe or a 
Rcan1 probe obtained from clone 2C3 in the SSH assay. A represen-
tative Northern blot from two independent experiments is shown. 
(B and C) BMMCs were sensitized with anti-TNP IgE and stimulated with 
10 ng/ml TNP-BSA for 15, 30, 60, or 180 min. RNA isolated from these cells 
was reverse transcribed to cDNA and subjected to real-time quantitative PCR. 
Rcan1 expression was normalized to endogenous control GAPDH. The 
data are expressed as relative mRNA levels compared with the mean 
expression level in BMMCs treated with TNP-BSA for 60 min (=1), be-
cause at this time point Rcan1 showed the highest expression level. The 
PCR products were also separated by agarose gel and stained with ethid-
ium bromide. Untreated BMMCs (NT) showed no Rcan1 expression, 
whereas TNP induced a strong Rcan1 expression. Error bars represent SEs 
from three independent experiments. (D) IgE-sensitized BMMCs were 
treated with TNP-BSA for 2, 4, or 6 h. Cell lysates were analyzed by West-
ern blotting for Rcan1. TNP-induced Rcan1 expression was observed in 
wild-type BMMCs (Rcan1  +/+  ). Lysate from Rcan1-defi  cient BMMCs 
(Rcan1     /    ) after TNP treatment (2 h) was used as a control. Membrane 
was stripped and probed for actin as a loading control. A representative 
Western blot from two independent experiments is shown.     198 NEGATIVE REGULATION OF I  G  E-INDUCED MAST CELL ACTIVATION BY RCAN1   | Yang et al. 
    Figure 2.           Rcan1   defi  ciency leads to increased IgE-dependent NFAT activation.   (A)  Rcan1 +/+   and  Rcan1    /     BMMCs were transfected with a 
pNFAT-Luc and the control reporter plasmid pRL-TK. After transfection (24 h), cells were sensitized with anti-TNP IgE for 18 h. Then cells were either left 
untreated (NT) or treated with 10 ng/ml TNP-BSA for 18 h (TNP). Firefl  y and Renilla activities were sequentially quantifi  ed using a dual-luciferase re-
porter assay system. Data are means   ±   SEM (  n   = 3 independent experiments). *, P   <   0.05 compared with wild-type group. (B) NFAT binding concensus 
sequence (N) on mouse IL-13 promoter 5   -AAGGTGTTTCCCCAAGCCTTTCCC-3    was labeled with   32  P for EMSA. After sensitization with anti-TNP IgE, 
Rcan1  +/+   and Rcan1     /     BMMCs were either not treated (NT) or stimulated with 10 ng/ml TNP-BSA for 5, 20, 60, 180, and 360 min. Nuclear proteins were 
isolated and subjected to EMSA. Shown is a representative from six independent experiments. (C) Densitometry analysis of NFAT activation by EMSA was 
performed based on six experiments. *, P   <   0.05 compared with the same time point of the wild-type group (180 or 360 min). (D) Nuclear extracts from 
Rcan1  +/+   and Rcan1     /     BMMCs were used for competition assays. 50  ×   concentrated unlabeled NFAT probe (N) was used to compete with the   32 P-
labeled NFAT probe, whereas 50  ×   concentrated unlabeled mutant NFAT probe (Nm; 5   -AAGGTGT CCAT CCAAGCCT CCTA C-3   ) was used as a control. 1   μ  l of 
nonradiolabeled wild-type NFAT probe (N) or mutant probe Nm were added and incubated for 15 min before the addition of the radiolabeled probe. 
(E) Antibody blockade of the DNA  –  protein complex formation (supershift assay). Nuclear proteins from BMMCs treated for 1 h with 10 ng/ml TNP-BSA 
were incubated with or without specifi  c antibodies to NFATc1 or NFATc2 for 30 min on ice before EMSA experiments using the   32  P-labeled NFAT probe 
(N). Shown is a representative from three (D) or two (E) independent experiments. (F) Rcan1  +/+   and  Rcan1    /     BMMCs were treated with 10 ng/ml TNP-
BSA for 6 h or left untreated. Cells were lysed, and calcineurin activity was analyzed by using a calcineurin assay kit according to the manufacturer  ’  s 
instructions. Error bars represent SE (  n   = 4). *, P   <   0.05 compared with the TNP-treated Rcan1  +/+   group.   JEM VOL. 206, January 19, 2009 
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As shown in   Fig. 3 A  ,   Rcan1  -defi  cient BMMCs showed 
signifi  cantly enhanced NF-    B activity in response to TNP 
stimulation, suggesting that Rcan1 is needed for the nega-
tive regulation of Fc    RI-mediated NF-    B activation.   NF-    B 
activity is regulated by I    B. The eff  ects of Rcan1 on Fc    RI-
mediated I    B phosphorylation and degradation were exam-
ined by Western blotting. Aggregation of Fc    RI induced a 
rapid phosphorylation of I    B (5 min), followed by I    B deg-
radation (5 and 20 min) and subsequent regeneration of this 
molecule (60, 180, and 360 min;   Fig. 3 B  ). Interestingly, the 
early events of I    B phosphorylation and degradation at 5 and 
20 min were not aff  ected by   Rcan1   defi  ciency. In contrast, 
phosphorylation at the later time point (60 min) was signifi  -
cantly enhanced in   Rcan1  -defi  cient BMMCs (  Fig. 3 B  ). This 
process was associated with an increased regeneration of I    B     
at 60 min after TNP-BSA stimulation (Fig. S5, available at 
http://www.jem.org/cgi/content/full/jem.20081140/DC1). 
These results suggest that Rcan1 is likely involved in   “  turning 
off    ”   Fc    RI-mediated activation signals, a notion consistent 
with that in NFAT signaling. 
  MAPKs represent a distinct mechanism in the regulation 
of mast cell function. Previous studies have established a ma-
jor role of the MAPKs c-Jun N-terminal kinase (JNK) and 
p38 in Fc    RI-mediated mast cell activation (  20, 21  ). Ac-
cordingly, we tested whether Rcan1 aff  ects Fc    RI-mediated 
JNK and p38 signaling. Cell lysates from TNP-stimulated 
BMMCs were subjected to Western blotting for phospho-
JNK, phospho-p38, and their total proteins. As shown in 
  Fig. 3 C  , TNP stimulation induced an increase of p38 phos-
phorylation (5 min) and JNK phosphorylation (20 min). 
Subsequently, levels of p38 and JNK phosphorylation re-
turned to basal conditions (180  –  360 min). Similar patterns of 
TNP-induced phosphorylation (the increase in the early 
phase and decrease in the late phase) of p38 and JNK were 
observed for   Rcan1  -defi  cient and wild-type mast cells. These 
data suggest that Rcan1 is not required for Fc    RI-mediated 
MAPK activation and inactivation processes. We also tested 
Akt phosphorylation, which is involved in the activation of 
the PI3K pathway. Similarly, no diff  erence in the Akt phos-
phorylation pattern was observed between   Rcan1  -defi  cient 
and wild-type BMMCs (  Fig. 3 C  ). In addition, a similar pat-
tern of Fc    RI-mediated Syk phosphorylation was observed 
between wild-type and   Rcan1  -defi  cient BMMCs (  Fig. 3 C  ). 
    Rcan1   defi  ciency leads to enhanced IL-6, IL-13, 
and TNF production in response to TNP stimulation 
  Several cytokines such as IL-6, IL-13, and TNF play impor-
tant roles in allergy and are regulated by the transcription fac-
tors NFAT and NF-    B. To determine whether Rcan1 is 
involved in the regulation of Fc    RI-mediated cytokine 
    Figure 3.           Rcan1   defi  ciency induces increased IgE-dependent NF-
    B activation but not MAPK, Akt, or Syk.   (A)  Rcan1 +/+   and  Rcan1    /    
BMMCs were transfected with a pNF-    B-Luc and the control reporter 
plasmid pRL-TK. After transfection (24 h), cells were sensitized with anti-
TNP IgE for 5 h. Cells were then either left untreated (NT) or treated with 
10 ng/ml TNP-BSA for 18 h (TNP). Firefl  y and Renilla activities were se-
quentially quantifi  ed using a dual-luciferase reporter assay system. Data 
are means   ±   SEM (  n   = 3 independent experiments). *, P   <   0.05 compared 
with the wild-type group. (B and C) Rcan1  +/+   and  Rcan1    /     BMMCs  were 
sensitized with anti-TNP IgE and stimulated with TNP-BSA for various 
times. Total cell lysates were analyzed by Western blotting for various 
phosphorylated and total proteins. Increased I    B phosphorylation in 
Rcan1     /     BMMCs was found at 60 min after TNP stimulation when 
compared with Rcan1  +/+   cells. In contrast, the pattern of TNP-induced 
phosphorylation of p38, JNK, Akt, and Syk is similar between Rcan1     /    
and Rcan1  +/+   BMMCs.   
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level, whereas the mRNA expression of these cytokines was 
prolonged in   Rcan1  -defi  cient cells (  Fig. 4, D  –  I  ). Enhanced 
production of IL-6, IL-13, and TNF at the protein level is 
likely caused by the prolonged mRNA expression of these 
cytokines. The prolonged mRNA expression of these cyto-
kines supports the notion that Rcan1 functions as a negative 
regulator by turning off   Fc    RI-activated signals. This is con-
sistent with the negative role of Rcan1 in the regulation of 
Fc    RI-induced NFAT and I    B  –  NF-    B activation. 
  To further determine a role of Rcan1 in Fc    RI-mediated 
cytokine production, wild-type and  Rcan1  -defi  cient BMMCs 
were transfected with Rcan1-pCMV vector or empty vector 
pCMV. These cells were then sensitized with anti-TNP IgE 
and stimulated with TNP-BSA. Cell supernatants were col-
lected for testing cytokine production. Both wild-type and 
  Rcan1  -defi  cient cells transfected with Rcan1-pCMV showed 
production,   Rcan1  -defi   cient and wild-type BMMCs were 
sensitized with anti-TNP IgE and stimulated with TNP-BSA 
for various times. IL-6, IL-13, and TNF production in cell-
free supernatants was determined by ELISA. Expression of 
these cytokine mRNAs was analyzed by real-time quantita-
tive PCR using total RNA isolated from cell pellets. Produc-
tion of IL-6 was signifi  cantly enhanced by 87, 170, and 115% 
at the time points of 3, 6, and 18 h, respectively, in   Rcan1  -defi  -
cient BMMCs compared with wild-type BMMCs (  Fig. 4 A  ).   
Importantly, real-time PCR analysis revealed that TNP-
BSA  –  induced IL-6 mRNA expression was prolonged in 
  Rcan1  -defi  cient BMMCs (  Fig. 4 B  ). PCR-amplifi  ed prod-
ucts separated by agarose gel electropheresis also revealed a 
prolonged TNP-BSA  –  induced IL-6 expression in   Rcan1  -de-
fi  cient BMMCs (  Fig. 4 C  ). Similarly, TNP-BSA  –  induced 
IL-13 and TNF production was enhanced at the protein 
    Figure 4.           Rcan1   defi  ciency leads to enhanced IgE-dependent production of IL-6, IL-13, and TNF.   After sensitization with anti-TNP IgE for 24 h, 
Rcan1  +/+   and Rcan1     /     BMMCs were either not treated (NT) or stimulated with TNP-BSA for various times. Cell-free supernatants were collected for the de-
tection of IL-6 (A), IL-13 (D), and TNF (G) by ELISA. Cell pellets were used for RNA isolation and analysis for cytokine mRNA expression. Real-time quantitative 
PCR was performed to determine IL-6 (B), IL-13 (E), and TNF (H) expression. IL-6, IL-13, and TNF expression was normalized to endogenous control GAPDH. The 
PCR products for IL-6 (C), IL-13 (F), and TNF (I) were also separated by agarose gel and stained with ethidium bromide. Untreated BMMCs (NT) showed little 
cytokine expression, whereas TNP induced enhanced cytokine production in Rcan1     /     BMMCs. Error bars represent SEs from six independent experiments 
(A, B, D, E, G, and H). Results presented in C, F, and I are representative of three to six separate experiments. *, P   <   0.05 compared with the wild-type group.    JEM VOL. 206, January 19, 2009 
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between Egr1 and Rcan1 in mast cells and prompted us to an-
alyze the promoter sequence of   Rcan1  , where we identifi  ed a 
putative Egr1 binding domain (  Fig. 7 B  ). 
    Rcan1   promoter contains Egr1 binding activity 
  To determine whether the putative Egr1 binding sequence 
on the   Rcan1   promoter between     158 and     142 is func-
tional, we generated a series of constructs for a luciferase assay 
containing various regions of the   Rcan1   promoter. All con-
structs start at     67 bp from the ATG codon. The 5     end of 
each construct varies to include diff  erent parts of the putative 
Egr1 binding sequence (  Fig. 7 C  , left). Mouse BMMCs were 
transfected with these constructs, sensitized with anti-TNP 
IgE, and stimulated with TNP-BSA. Luciferase activity was 
determined. As shown in   Fig. 7 C  , both constructs pR-
luc283 and pR-luc158, which contain the full length of the 
Egr1 binding sequence from     158 to     142, showed strong 
luciferase activity. The construct pR-luc154, which contains 
a partial Egr1 binding sequence from     154 to     142, showed 
decreased IL-6 and TNF production after TNP-BSA stimu-
lation, suggesting that forced expression of Rcan1 reduced 
Fc    RI-mediated cytokine production (  Fig. 5  ).   
    Rcan1   defi  ciency leads to enhanced Fc    RI-mediated 
late-phase cutaneous reaction in vivo 
  Mast cell  –  derived cytokines contribute to the development of 
late-phase allergic reactions (  22, 23  ). To examine whether 
Rcan1 contributes to Fc    RI-mediated late-phase cutaneous 
reaction in vivo, mice were sensitized with anti-DNP IgE 
24 h before a solution of 0.3% dinitrofl  uorobenzene (DNFB; 
hapten) was applied epicutaneously to the ear skin or footpad. 
IgE/antigen-specifi  c edema was determined by tissue weight 
and thickness.   Rcan1  -defi  cient mice exhibited increased IgE/
antigen-specifi  c edema when measured by tissue weight 
(  Fig. 6, A and B  ).   Tissue thickness, measured by a digital mi-
crometer, also showed similar results (  Fig. 6, C and D  ). These 
fi  ndings are consistent with the increased IL-6, IL-13, and 
TNF production by   Rcan1  -defi  cient BMMCs in vitro  .   
    Rcan1   defi  ciency leads to enhanced Fc    RI-mediated mast cell 
degranulation and passive cutaneous anaphylaxis in vivo 
  To examine whether Rcan1 plays a role in IgE-dependent mast 
cell degranulation, wild-type and   Rcan1  -defi  cient BMMCs 
were sensitized with anti-TNP IgE and stimulated with 
TNP-BSA for 20 min. Mast cell degranulation was deter-
mined by testing     -hexosaminidase release. Increased mast 
cell degranulation was observed in   Rcan1  -defi  cient mast cells 
(  Fig. 6 E  ). Mast cell mediators released by degranulation con-
tribute to the anaphylactic reactions in vivo. To examine 
whether   Rcan1   defi  ciency aff  ects passive cutaneous anaphy-
laxis in vivo, the left ears of mice were passively sensitized 
with 20 ng anti-DNP IgE, whereas the right ears were in-
jected with saline as a control. 24 h later, mice were injected 
with 100   μ  g DNP-BSA containing Evans blue dye via the tail 
vein. 30 min later, tissues from both ears were collected for 
extraction of Evans blue dye to determine vascular permea-
bility. Increased vascular permeability (passive cutaneous ana-
phylaxis) was observed in   Rcan1  -defi  cient mice (  Fig. 6 F  ). 
  To exclude the possibility that the increased cutaneous 
allergic responses is caused by the abnormal mast cell devel-
opment in vivo, the ears, tongues, and back skin from   Rcan1  -
defi  cient and wild-type mice were used to examine the 
presence of mast cells. A similar number and morphology of 
mast cells were observed in tissues from   Rcan1  -defi  cient and 
wild-type mice (  Fig. 6, G and H  ). 
  Fc    RI-induced Egr1 expression precedes Rcan1 expression 
  Next, we examined how the negative Rcan1 signal is activated 
during Fc    RI activation. Our SSH assay using RNAs from 
TNP-BSA  –  stimulated BMMCs identifi  ed one clone (2A10) 
that matched the   Egr1   gene (Table S1). Real-time quantitative 
PCR analysis showed that   Egr1   gene expression peaked at 
15 min after TNP-BSA stimulation. In contrast, Rcan1 expres-
sion began to increase at 15 min and peaked at 60 min (  Fig. 7 A  ).   
These data suggested a sequential gene expression relationship 
    Figure 5.         Forced Rcan1 expression reduced IgE-dependent cytokine 
production.   Wild-type and   Rcan1 -defi  cient BMMCs were transfected with 
Rcan1-pCMV vector or control vector pCMV. These cells were then sensi-
tized with anti-TNP IgE and subsequently stimulated with 10 ng/ml TNP-
BSA for 6 h (TNP) or left untreated (NT). Cell-free supernatants were 
collected for the determination of IL-6 and TNF by ELISA. Error bars repre-
sent SE (  n   = 3). *, P   <   0.05 compared with the control pCMV vector group.     202 NEGATIVE REGULATION OF I  G  E-INDUCED MAST CELL ACTIVATION BY RCAN1   | Yang et al. 
    Figure 6.           Rcan1   defi  ciency leads to enhanced late-phase passive cutaneous anaphylaxis.   (A  –  D) Mice were passively sensitized by i.v. injection of 
2   μ  g anti-DNP IgE mAb. 24 h later, 20   μ  l of 0.3% DNFB in acetone/olive oil (4:1) was applied epicutaneously to both sides of the left hind paw or left ear, 
and 20   μ  l of acetone/olive oil was applied to the right hind paw or right ear as a control. 24 h later, the thickness of the foot pad and ear was measured 
using a digital micrometer. The weight of the hind paw and ear punch (5 mm) was also determined. The thickness and weight of the right ear or right 
hind paw that were treated with acetone/olive oil only were used as baseline values. The DNFB-induced increment of tissue thickness and weight was 
expressed as a percentage of the baseline values. Data are means   ±   SEM (  n   = 10 mice in each group). *, P   <   0.05 compared with wild-type mice. 
(E) BMMCs were sensitized with IgE and stimulated with TNP-BSA for 20 min. The release of     -hexosaminidase was determined. Data are means   ±   SEM (  n   = 3 
independent experiments). *, P   <   0.05 compared with wild-type BMMCs. (F) Passive cutaneous anaphylaxis. 20 ng anti-DNP IgE was injected intrader-
mally on the left ear, whereas the right ear received saline as a control. After 24 h, mice received 100   μ  g DNP-BSA containing Evan  ’  s blue dye (1% wt/vol) 
via tail vein injection. Ear punches (8 mm) of both ears were collected 30 min later and were used for extraction of the Evan  ’  s blue dye. The optical 
density was measured at 620 nm. Data are means   ±   SEM (  n   = 8 mice in each group). *, P   <   0.05 compared with the IgE group of the wild-type mice. 
(G and H) Back skin, tongue, or ear tissues from wild-type or   Rcan1 -defi  cient mice were fi  xed and stained by alcian blue for mast cells. Similar metachromatic 
staining between wild-type and   Rcan1 -defi  cient mast cells was observed. Specimens were viewed on a microscope (Eclipse E600; Nikon) equipped with a 
camera (DMX1200; Nikon) and a DDL 20  ×   or 40   ×  /0.75 objective lens. Acquisition was performed with Nikon ACT-1 software (version 2.20). Images were 
processed using Adobe Photoshop software (version 5.0). Slides shown are representative of sections taken from fi  ve mice per group. The number of mast 
cells was enumerated by counting 10 randomly selected fi  elds with a 40   ×  /0.75 objective lens (H). Data are means   ±   SEM (  n   = 10 fi   elds).  Bars,  5   μ m.   JEM VOL. 206, January 19, 2009 
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decreased luciferase activity. In contrast, the construct pR-
luc141, which does not contain an Egr1 binding region, and 
the empty plasmid pGL4-Basic showed little luciferase activ-
ity. This result suggests that the Egr1 binding sequence in the 
  Rcan1   promoter is functional. 
  To further confi  rm that the Egr1 binding sequence is 
functional in response to Fc    RI aggregation, we synthe-
sized a DNA probe containing the Egr1 binding sequence 
in the   Rcan1   promoter for a gel shift assay. Nuclear proteins 
were isolated from BMMCs after TNP-BSA stimulation 
and subjected to EMSA. Strong DNA binding was seen in 
TNP-BSA  –  stimulated cells (  Fig. 7 D  ). The binding speci-
fi  city was confi  rmed by competition with the nonradiola-
beled probe (E, unlabeled probe) but not with a mutant probe 
(Em, unlabeled probe;   Fig. 7 D  ). 
  Furthermore, a chromatin immunoprecipitation (ChIP) 
assay was performed to confi  rm Fc    RI-induced binding of 
Egr1 to the   Rcan1   promoter. Nuclei from TNP-BSA  –  stimu-
lated and unstimulated BMMCs were subjected to enzymatic 
digestion followed by immunoprecipitation using anti-Egr1 
or control antibodies. Immunoprecipitates were subjected to 
PCR using a pair of primers that amplify the   Rcan1   promoter 
region encompassing the Egr1 binding sequence. Specifi  c 
Egr1 binding to the   Rcan1   promoter was observed in TNP-
BSA  –  stimulated cells (  Fig. 7 E  , lane 8) but not in unstimulated 
cells (  Fig. 7 E  , lane 7). This result suggested that TNP-BSA 
stimulation induced Egr1 binding to the   Rcan1   promoter. 
  Rcan1 expression is diminished in the absence of Egr1 
  To evaluate whether Egr1 is required for Fc    RI-induced 
Rcan1 expression, we generated   Egr1  -defi  cient and wild-
type BMMCs.   Egr1  -defi  cient BMMCs mature normally and 
express similar levels of Fc    RI compared with wild-type 
    Figure 7.         Egr1 binds to and transactivates the   Rcan1   promoter.  
(A) RNA from TNP-BSA  –  treated BMMCs was analyzed by real-time quantita-
tive PCR for Egr1 and Rcan1. Egr1 and Rcan1 expression was normalized 
to endogenous control GAPDH. The data are expressed as relative mRNA 
levels compared with the mean expression level in BMMCs treated with 
TNP-BSA for 15 min (=1; Egr1) or for 60 min (=1; Rcan1), because at this 
time point Egr1 or Rcan1 showed the highest expression level, respec-
tively (  n   = 3 experiments). (B) The location and sequence of the Egr1 
binding site on the   Rcan1   promoter. (C) BMMCs were transfected with 
various plasmids generated from pGL4 containing different lengths of the 
Egr1 binding sequence and the control reporter plasmid pRL-TK. All con-
structs start at     67 bp relative to the ATG codon. The 5     end of each 
construct is shown at the left. Firefl  y and Renilla activities were sequen-
tially quantifi  ed using a dual-luciferase reporter assay system. Results are 
means   ±   SEM (  n   = 3). (D) Nuclear proteins from untreated (NT) or TNP-
BSA  –  treated BMMCs (TNP-BSA 1 h) were subjected to EMSA. An Egr1 
DNA probe was synthesized based on the Egr1 binding sequences on the 
  Rcan1   promoter (E). A mutant Egr1 DNA probe with two nucleotide mu-
tations was used for a competition assay (Em). Strong TNP-BSA  –  induced 
Egr1 binding was seen and was competed by the specifi  c cold probe (E) 
but not by the mutant probe (Em). Results are representative of three 
independent experiments. (E) ChIP assay for the association of Egr1 with 
  Rcan1   promoter in vivo. BMMCs were stimulated with TNP-BSA for 60 min 
or left unstimulated. Protein  –  DNA complexes were extracted and pre-
cipitated with anti-Egr1 antibody (Egr1) or control IgG (IgG). DNA from 
samples before immunoprecipitation (IP) was used as an input control 
(Input). PCR was performed using primers based on the   Rcan1   promoter 
sequence. Amplifi  ed DNA was resolved in agarose gel. Specifi  c Egr1 bind-
ing to the   Rcan1   promoter was seen in TNP-stimulated cells (lane 8) but 
not in unstimulated cells (lane 7). Results are representative of three in-
dependent experiments. M, molecular marker.     
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  It is noteworthy that Rcan1 selectively regulated Fc    RI-
mediated NFAT and NF-    B pathway but not MAPK and Akt 
activation. The activity of NFAT is regulated by its phosphor-
ylation state, which is controlled by the opposing action of the 
serine/threonine phosphatase, calcineurin, and the serine/
threonine kinase, glycogen synthase kinase 3     . Under resting 
conditions, NFAT is phosphorylated and localized in the cy-
toplasm. Upon stimulation, it is dephosphorylated by calci-
neurin and translocates to the nucleus. Studies have indicated 
that Rcan1 can bind to and inhibit calcineurin (  24  –  26  ). Thus, 
it is possible that Fc    RI-induced Rcan1 blocks NFAT acti-
vation through inhibition of calcineurin. Consistent with this 
model, we found that calcineurin activity was increased in 
  Rcan1  -defi  cient mast cells. Various pharmaceutical molecules 
targeting the calcineurin  –  NFAT pathway have successfully 
been used for the treatment of allergic infl  ammation (  16  ). 
This highlights the importance of the NFAT pathway in al-
lergic diseases. 
  In addition to NFAT activation, we also found that 
Fc    RI-induced I    B phosphorylation and NF-    B activity 
were enhanced in   Rcan1  -defi  cient mast cells. Rcan1 is able 
to regulate the NF-    B pathway through direct interaction 
with NF-    B  –  inducing kinase or I    B (  27, 28  ). In addition, 
calcineurin can dephosphorylate I    B, leading to the subse-
quent nuclear translocation of NF-    B (  15  ). Thus, Rcan1 
could also indirectly regulate the NF-    B pathway through 
calcineurin. Enhanced Fc    RI-induced I    B  –  NF-    B pathway 
activation in   Rcan1  -defi  cient mast cells likely contributes to 
the increased cytokine production and enhanced late-phase 
cutaneous allergic reactions. 
  Fc    RI-mediated mast cell production of cytokines such 
as IL-6, IL-13, and TNF may be benefi  cial or harmful in the 
setting of innate or allergic responses. Effi   cient production of 
mast cell mediators would be benefi  cial for the eff  ective de-
velopment of host defenses, whereas overproduction of mast 
cell mediators could be harmful. Accordingly, a temporal 
regulatory mechanism is necessary that allows the initial 
Fc    RI-mediated signaling to proceed in the early phase and 
permits the termination of the activated signal subsequently 
in a timely manner. We found that the new synthesis of 
Rcan1 was dependent on Egr1, which is synthesized de novo 
after Fc    RI stimulation (  6  ). These data suggest that activa-
tion signals, including Egr1, proceed to initiate infl  ammatory 
cytokine expression, but subsequently Rcan1 is induced, 
which serves as a negative regulator to inhibit Fc    RI-medi-
ated signals by inhibiting calcineurin activity. The new link 
of Egr1 and Rcan1 may represent a transition from activation 
to inhibition in Fc    RI signaling. 
    Rcan1   defi  ciency not only up-regulates cytokine produc-
tion, it also enhances IgE-dependent mast cell degranulation 
in vitro and passive cutaneous anaphylaxis in vivo. Calcineu-
rin activity has been associated with mast cell exocytosis (  29  ). 
Thus, it is possible that Rcan1 modulates IgE-dependent 
mast cell degranulation and passive cutaneous anaphylaxis 
through inhibiting calcineurin activity. However, a recent 
paper demonstrated that Rcan1 regulates vesicle exocytosis 
BMMCs. BMMCs were sensitized with anti-TNP IgE and 
stimulated with TNP-BSA. Total RNA was isolated and an-
alyzed by real-time quantitative PCR for Rcan1 (isoform 
Rcan1-4) expression. TNP-BSA  –  induced Rcan1 expression 
was signifi  cantly reduced in   Egr1  -defi  cient BMMCs (  Fig. 8 A  ).   
A PCR-amplifi  ed   Rcan1   product (Rcan1-4) was also sepa-
rated on an agarose gel. A representative gel is presented in 
  Fig. 8 B  . Reduced Rcan1 expression in   Egr1  -defi  cient BMMCs 
can be seen after TNP-BSA stimulation. Thus, Egr1 is re-
quired for Fc    RI-induced Rcan1 expression. 
    DISCUSSION   
  The present study demonstrates an as of yet unknown pathway 
linking activation to inhibition in Fc    RI-mediated signaling. 
Notably, we found that an Fc    RI aggregation  –  induced activa-
tion signal initiates de novo synthesis of Rcan1. Rcan1 was 
identifi  ed as a negative regulator, required for turning off   
Fc    RI-activated signals. Fc    RI-mediated Rcan1 inhibits calci-
neurin activity, which leads to down-regulation of NFAT and 
NF-    B activation, and subsequent cytokine production and 
inhibition of late-phase allergic reactions. Moreover, Rcan1 is 
also required for the negative regulation of mast cell degranula-
tion and acute passive cutaneous anaphylaxis. Thus, both the 
preformed mediator release and the production of newly syn-
thesized cytokines are negatively regulated by Rcan1. 
    Figure 8.         Egr1 is required for Rcan1 expression.   (A and B) After 
sensitization with anti-TNP IgE for 24 h, Egr1  +/+   and  Egr1    /     BMMCs  were 
either not treated (NT) or stimulated with TNP-BSA for 1 h. RNA was iso-
lated and analyzed by real-time quantitative PCR for Rcan1. Rcan1 ex-
pression was normalized to endogenous control GAPDH. The data are 
expressed as relative mRNA levels compared with the mean expression 
level in Egr1  +/+   BMMCs treated with TNP-BSA for 60 min (=1), because in 
this group Rcan1 showed the highest expression level (A). Error bars rep-
resent SEs from three independent experiments. *, P   <   0.05 compared 
with the wild-type group. The PCR products were also separated by aga-
rose gel and stained with ethidium bromide (B). A representative gel from 
three independent experiments is shown. M, molecular marker.     JEM VOL. 206, January 19, 2009 
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Cruz Biotechnology, Inc.) was added and incubated for 30 min before the 
addition of the radiolabeled probe. 
  Real-time quantitative PCR.     The mRNA levels of various genes were 
quantifi  ed using TaqMan MGB probes and TaqMan Master Mix on a se-
quence detection system (ABI Prism 7000; Applied Biosystems). GAPDH 
was used as an endogenous reference. Data were analyzed using the relative 
standard curve method according to the manufacturer  ’  s protocol. A mean 
value of each gene after GAPDH normalization at the time point showing 
highest expression was used as a calibrator to determine the relative levels of 
Rcan1, IL-6, TNF, IL-13, I    B    , or Egr1 at diff  erent conditions. In addi-
tion, PCR products were resolved on a 2% agarose gel and stained with 
ethidium bromide. 
  Western blot analysis.     Cells lysates (20  –  30   μ  g) were subjected to electro-
phoresis in 12% SDS-polyacrylamide gels. Gels were transferred to polyvi-
nylidene difl  uoride membrane, blotted with primary and secondary antibodies, 
and detected by an enhanced chemiluminescence detection system (Western 
Lightning Plus-ECL; PerkinElmer). 
  Rcan1 expression vector and transfection.     Rcan1 expression vector 
was constructed by inserting the   Rcan1   gene into pCMV plasmid. BMMCs 
were resuspended at 4   ×   10  6   cells/transfection in Amaxa nucleofector solu-
tion and electroporated with 8   μ  g DNA using Amaxa Nucleofector Device 
(program U-023). After 24 h, mast cells were sensitized with IgE for 18 h 
and challenged with 10 ng/ml TNP-BSA for 6 h. 
  Calcineurin activity assay.     Phosphatase activity was measured using a 
calcineurin assay kit (BIOMOL International L.P.). Wild-type and   Rcan1  -
defi  cient BMMCs were sensitized with IgE and stimulated with 10 ng/ml 
TNP-BSA for 6 h. Lysates were prepared, and phosphatase activity was 
measured according to the manufacturer  ’  s instructions. 
  ChIP.     ChIP assays were performed using the ChIP-IT kit (Active Motif) 
according to the manufacturer  ’  s instructions. In brief, BMMCs were fi  xed 
with 1% formaldehyde, and the nuclei were subjected to an enzymatic di-
gestion with 5 U of enzymatic shearing cocktail solution for 25 min at 37  °  C. 
Sheared chromatin was immunoprecipitated with 4   μ  g Egr1 (Santa Cruz 
Biotechnology, Inc.) or control IgG (Active Motif). 0.4% of the input DNA 
and 5% of the precipitated DNA were then used as templates for each PCR, 
consisting of 36 cycles of 20 s at 94  °  C, 30 s at 59  °  C, and 30 s at 72  °  C. PCR 
products were separated by a 2% agarose gel. Primers for amplifi  cation of the 
  Rcan1   promoter region were 5    -AGCAAACCTTAGCGCCTTTT-3     
(forward) and 5    -AAGAGAACGAGCGAGACCAC-3     (reverse). 
  Construction of luciferase plasmids.     The plasmid pGL4.10 [Luc2] (Pro-
mega) was used to construct pR-Luc plasmids containing   Rcan1   promoter 
fragments. A fragment of the   Rcan1   promoter (    283 to     67, relative to the 
transcription start site) was generated by PCR with the forward primer 
5    -G  CTCTAG  ACTAAGGTGTTGACGTCACC-3     (  XbaI   site underlined) and 
the reverse primer 5    -TTT  AAGCTT  CCTTTGCAAGAGAACGAGCG-3     
(  HindIII   site underlined). The PCR product was purifi  ed, digested with   XbaI   
and   HindIII  , and ligated into the   NheI  /  HindIII   sites of pGL4.10 using T4 DNA 
ligase and sequenced to verify orientation. It was designated as pR-Luc283. To 
generate progressive 5    -unidirectional truncations by PCR, a series of forward 
primers was used in combination with the same reverse primer and pR-Luc283 
as the template. The forward primers began with     158 (5    -CTGGAAGC-
CA  AGATCT  CCCCG-3    ;   BglII   site underlined),     154 (5    -GAAGC-
CAAGC  GGTACC  GCCC-3    ;   KpnI   site underlined), and     141 (5    -CCAGG
  CAGCTG  GCTCTCCGCG-3    ;   PvuII   site underlined). The purifi  ed PCR 
products were digested with corresponding restriction enzymes, treated with 
mung bean exonuclease, and subcloned into the   EcoRV/HindIII   sites of 
pGL4.10. They were designated pR-Luc158, pR-Luc154, and pR-Luc141, 
respectively. Each construct was verifi  ed by sequencing the insert and plasmid-
fl  anking region. 
and fusion pore kinetics through novel unknown mecha-
nisms other than calcineurin (  30  ). Indeed, Rcan1 also directly 
interacts with several additional targets other than calcineurin. 
These include Raf-1 (  31  ), 14-3-3 (  32  ), and NF-    B  –  inducing 
kinase (  28  ). All of these molecules have been directly or indi-
rectly associated with exocytosis. 
    RCAN1   was fi  rst identifi  ed as an expressed sequence on 
a yeast artifi  cial chromosome clone from human chromo-
some 21 (  33  ). The   Rcan1   gene consists of seven exons, of 
which exons 1  –  4 can be alternatively transcribed to produce 
diff  erent mRNA isoforms (  17  ). Members of this new Rcan 
family also include Rcan2 and Rcan3 (  17  ). The functional 
distinctions among these family members are unclear. It is 
interesting to note that the isoform of Rcan1-4, which is 
encoded by exons 4, 5, 6, and 7, was the only member to be 
up-regulated by Fc    RI aggregation. This result suggests that 
this isoform may be functionally distinct from the other 
family members. 
  Egr1 can be induced by a variety of stimuli such as sepsis 
(  34  ) and tissue injuries (  35  ). Rcan1 has also been associated 
with several diseases (  36  ). The link between Egr1 and Rcan1 
identifi  ed in this study will off  er unforeseen potential for the 
regulation of signaling in a wide range of Egr1- and Rcan1-
associated physiological processes and human diseases. 
  MATERIALS AND METHODS 
  Animals.       Rcan1  -defi  cient mice were generated as previously described (  18  ). 
  Egr1  -defi  cient mice and control C57BL/6NTac mice were purchased from 
Taconic. The protocols were approved by the University Committee on 
Laboratory Animals, Dalhousie University, in accordance with the guide-
lines of the Canadian Council on Animal Care. 
  Antibodies.     Antibody to Rcan1 (AP6315c) was purchased from Abgent 
Inc. Antibodies to phospho-JNK (Thr 183/Tyr 185), JNK, phospho-p38 
MAPK (Thr 180/Tyr 182), phospho-Syk (Tyr 352), phospho-Akt (Ser 
473), and Akt were purchased from Cell Signaling Technology. Antibodies 
to p38 MAPK and actin were purchased from Santa Cruz Biotechnology, 
Inc. FITC-conjugated rat anti  –  mouse CD117 (c-kit) mAb and FITC  –  rat 
IgG2a were purchased from Cedarlane Laboratories Ltd. FITC-conjugated 
rat anti  –  mouse IgE (IgG1) and FITC  –  rat IgG1 were purchased from BD. 
  Mast cell culture and activation.     Mouse primary cultured BMMCs were 
cultured as previously described (  6  ). BMMCs were passively sensitized with 
IgE from TIB-141 cells (American Type Culture Collection). Cells were 
then stimulated with 10 ng/ml TNP-BSA (Biosearch Technologies). Mast 
cell degranulation was determined by measuring     -hexosaminidase release. 
  Nuclear extract preparation and EMSA.     Nuclear protein extracts 
were obtained using a nuclear extract kit (Active Motif) according to the 
manufacturer  ’  s protocol. EMSA was performed as previously described (  6  ). 
The following synthesized double-stranded oligonucleotides (Sigma-
Aldrich) were used: NFAT binding concensus sequence (N) on mouse IL-13 
promoter 5    -AAGGTGTTTCCCCAAGCCTTTCCC-3     and the mutant 
sequence (mutant Nm) 5    -AAGGTGT  CCAT  CCAAGCCT  CCTA  C-3    ; 
and Egr1 binding concensus sequence (E) on   Rcan1   promoter 5    -TCCCC-
GCCCCCAGGGGGCTGGCTCTCC-3     and the mutant sequence (Em) 
5    -TCCCC  TA  CCCCAGGGGGCTGGCTCTCC-3     (italics indicate mu-
tated sequences). For competition assays, 1   μ  l nonradiolabeled wild-type or 
mutant oligonucleotides (50-fold excess of radiolabeled probe) were added 
and incubated for 15 min before the addition of the radiolabeled probe. For 
supershift assay, 4   μ  g NFATc1 (Thermo Fisher Scientifi  c) or NFATc2 (Santa 206 NEGATIVE REGULATION OF I  G  E-INDUCED MAST CELL ACTIVATION BY RCAN1   | Yang et al. 
punch (5 mm) was also determined. The thickness and weight of the right 
ear or right hind paw (treated with acetone/olive oil only) were used as 
baseline values. The DNFB-induced increment of tissue thickness and 
weight was expressed as a percentage of the baseline values. 
  Statistical analysis.     Analysis of variance and the paired Student  ’  s   t   test were 
used for statistical evaluation of data. Results were considered signifi  cant 
when P   <   0.05. Throughout the paper, data are expressed as means   ±   SEM. 
  Online supplemental materials.     Fig. S1 shows the subtraction effi   ciency 
of the SSH method using RNAs from TNP-stimulated and unstimulated 
mast cells. Fig. S2 shows the gene location of the clones identifi  ed by SSH. 
Fig. S3 shows normal maturation of BMMCs from   Rcan1  -defi  cient mice. 
Fig. S4 shows increased nuclear translocation of NFAT in   Rcan1  -defi  cient 
mast cells compared with wild-type mast cells after TNP-BSA stimulation. 
Fig. S5 shows increased I    B     synthesis (particularly at 60 min) in   Rcan1  -de-
fi  cient mast cells after TNP-BSA stimulation. Table S1 shows eight Rcan1 
clones and one Egr1 clone identifi  ed by SSH. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20081140/DC1. 
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